Eloxx Pharmaceuticals, Inc. Cash Flow Conversion Efficiency
Eloxx Pharmaceuticals, Inc. cash flow conversion efficiency. Based on the latest financial reports, Eloxx Pharmaceuticals, Inc. (ELOX) has a cash flow conversion efficiency ratio of -0.103x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-4.79 Million) by net assets ($46.42 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of Eloxx Pharmaceuticals, Inc. (2004–2025)
Cash flow conversion efficiency of Eloxx Pharmaceuticals, Inc. from 2004 to 2025. This chart illustrates how Eloxx Pharmaceuticals, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. View ELOX stock price and chart for real-time trading data and today's change.
Eloxx Pharmaceuticals, Inc. Cash Flow Conversion Ratio Explained
Eloxx Pharmaceuticals, Inc. cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
Eloxx Pharmaceuticals, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Eloxx Pharmaceuticals, Inc. ranked by their cash flow conversion efficiency. Also see Eloxx Pharmaceuticals, Inc. market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Mackolik Internet Hizmetleri Ticaret A.S.
IS:MACKO
|
0.071x |
|
Li-FT Power Ltd.
F:WS0
|
-0.002x |
|
GrabAGun Digital Holdings Inc.
NYSE:PEW
|
N/A |
|
LUOYANG GLASS CO. H YC 1
F:LUG
|
N/A |
|
CHEET.M.ADR 50 NEW
F:0C9
|
N/A |
|
UIL Co. Ltd
KQ:049520
|
0.085x |
|
Transat AT Inc
TO:TRZ
|
0.257x |
|
TechPrecision Corporation Common stock
NASDAQ:TPCS
|
0.249x |
Annual Cash Flow Conversion Efficiency for Eloxx Pharmaceuticals, Inc. (2004–2025)
The table below shows the annual cash flow conversion efficiency of Eloxx Pharmaceuticals, Inc. from 2004 to 2025. Review Eloxx Pharmaceuticals, Inc. free cash flow ratio to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-11.91 Million | $-6.33 Million | 0.531x | +174.25% |
| 2024-12-31 | $-24.34 Million | $-4.71 Million | 0.194x | -69.47% |
| 2023-12-31 | $-22.60 Million | $-14.34 Million | 0.635x | -78.76% |
| 2022-12-31 | $-10.66 Million | $-31.84 Million | 2.987x | +291.05% |
| 2021-12-31 | $22.38 Million | $-35.00 Million | -1.564x | +43.21% |
| 2020-12-31 | $10.23 Million | $-28.17 Million | -2.753x | -153.11% |
| 2019-12-31 | $36.21 Million | $-39.39 Million | -1.088x | -48.81% |
| 2018-12-31 | $42.91 Million | $-31.37 Million | -0.731x | +2.01% |
| 2017-12-31 | $21.36 Million | $-15.94 Million | -0.746x | +7.45% |
| 2016-12-31 | $4.56 Million | $-3.68 Million | -0.806x | -34.17% |
| 2015-12-31 | $12.22 Million | $-7.34 Million | -0.601x | -239.27% |
| 2014-12-31 | $27.49 Million | $-4.87 Million | -0.177x | +82.37% |
| 2013-12-31 | $3.89 Million | $-3.90 Million | -1.004x | +18.65% |
| 2012-12-31 | $3.55 Million | $-4.39 Million | -1.235x | -3.44% |
| 2011-12-31 | $4.52 Million | $-5.39 Million | -1.193x | -100.82% |
| 2010-12-31 | $7.98 Million | $-4.74 Million | -0.594x | +15.00% |
| 2009-12-31 | $5.67 Million | $-3.96 Million | -0.699x | -185.88% |
| 2008-12-31 | $9.84 Million | $-2.41 Million | -0.245x | +67.62% |
| 2007-12-31 | $2.69 Million | $-2.03 Million | -0.755x | +11.88% |
| 2006-12-31 | $2.95 Million | $-2.53 Million | -0.857x | -126.45% |
| 2005-12-31 | $5.59 Million | $-2.12 Million | -0.379x | +5.42% |
| 2004-12-31 | $4.73 Million | $-1.89 Million | -0.400x | -- |
About Eloxx Pharmaceuticals, Inc.
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule product candidates that modulate the ribosome and promote readthrough of premature stop codons caused by nonsense mutations in the United States, Israel, and Australia. The company is developing exaluren, a eukaryotic ribosome-selective glycoside in a Phase 2 trial for the treatment of rare kidney dis… Read more